When Montrail Moore received a devastating leukemia diagnosis at 48 years old, his medical team at Franciscan Health in Indianapolis delivered harsh news. The aggressive progression of the disease required a prompt bone marrow transplant to swap his compromised cells for healthy donor tissue. Unfortunately, neither his relatives nor the global living donor registry yielded a compatible match.

A breakthrough option emerged through his oncologist: a transplant utilizing a deceased donor's tissue preserved via cryopreservation at an Indianapolis biobank. Moore underwent the procedure in January, sparking a remarkable recovery that he now celebrates as his personal rebirth. “It gave me a new life,” he shares regarding the milestone.

Pioneering Deceased-Donor Bone Marrow Technology

Moore’s successful intervention marks one of 29 completed procedures utilizing harvested and frozen bone marrow pioneered by Ossium Health. Operating out of San Francisco, the startup has maintained a flawless success rate across its clinical trials and compassionate use programs. The firm recently treated its inaugural pediatric patient, a 14-year-old boy, earlier this year. Looking ahead, Ossium plans to commercialize its deceased-donor bone marrow for blood cancers by next February, laying the groundwork for a broader stem-cell therapy portfolio.

“There were a lot of people that told us that what we were doing was nuts, and particularly a lot of doctors told us it was nuts,” notes Ossium co-founder and CEO Kevin Caldwell. “Doctors had never considered getting bone marrow from a deceased donor and they just assumed it would not be as good or it would not work.”

Overcoming Cryopreservation Challenges

While organs like hearts and lungs demand rapid transplantation within hours of death due to freezing damage, bone marrow uniquely withstands cryopreservation thanks to the resilient nature of stem cells. Historically, physicians depended entirely on living donors, raising clinical questions regarding the efficacy and safety of frozen marrow compared to traditional methods.

A decade ago, former McKinsey healthcare consultant Kevin Caldwell, 40, partnered with cryopreservation expert Erik Woods, 54. The duo hypothesized that utilizing deceased-donor bone material typically discarded by organ procurement organizations could eliminate matching delays and grant patients on-demand access to lifesaving treatments.

Funding, Growth, and Future Projections

Ossium has successfully secured $158 million from prominent backers including First Round Capital and General Catalyst, achieving a $300 million valuation during its 2023 funding round. Revenue projections point to $35 million this year—a 75% increase from the previous year's $20 million. Caldwell anticipates a breakout year in the near future, expecting revenue to exceed $120 million alongside a surge in annual transplants toward an eventual goal of treating over 10,000 patients yearly.

  • Successfully completed 29 transplant procedures without a single failure.
  • Secured a $125 million contract with BARDA for strategic radiological reserves.
  • Advanced spine and orthopedic applications via proprietary OssiGraft products.

By transforming medical logistics and unlocking the dense red bone marrow found within spinal vertebral bodies—regions inaccessible in living donors—Ossium continues to redefine cellular therapeutics on a global scale.